Due to the limited number of studies on the efficacy and safety of promising targeted therapies (FLT3, BCL-2, and CDK6 inhibitors) in the treatment of AML with NUP98 rearrangements, intensive chemotherapy and HSCT are currently the most important treatments [117,118]. This evidence concerns the gene NUP98 and acute myeloid leukemia.